Neurology Flashcards
Focal seizure
affects one side of the brain
Aware or impaired awareness
Motor or nonmotor
Focal or bilateral tonic-clonic
Generalized onset
Affects both sides of the brain
Absence (nonmotor)
Myoclonic (motor) - brief jerking movements
Tonic-clonic
5 phases:
Flexion
Extension
Tremor
Clonic
Postictal
Status epilepticus
Prolonged seizure of >5 minutes
After 30 minutes, long-term consequences possible
Automatisms
Associated with focal seizures - may occur before seizure
Lip smacking, chewing, swallong, tongue movements, scratching, thrashing arms/legs, fumbling with clothing, snapping fingers
Carbamazepine alleles
HLA-B*1502 - increased risk of SJS (Asian population)
HLA-B*3101 - increased risk of hypersensitivity (not tested routinely)
Phenytoin equivalents (PE)
1.5mg fosphenytoin = 1mg phenytoin (1 PE)
Dosing, administration rate fosphenytoin
Load: 10-20mg PE/kg IV or IM
Maintenance: 4-6 PE/kg/day in divided doses after load
Max infusion rate 150mg PE per minute (risk of severe hypotension, cardiac arrhythmias)
Less risk of phlebitis than phenytoin
Lamotrigine & Valproic Acid
Valproic acid decreases lamotrigine concentration
Lower starting and maintenance doses of lamotrigine needed to prevent ADRs
Estrogen effects on antiepileptics
Lamotrigine: estrogen OCPs increase clearance of lamotrigine so higher doses needed
Valproic acid: estrogen OCPs decrease VPA serum concentration
Antiepiletic drugs that are enzyme inducers
Carbamazepine
Cenobamate (CYP3A4)
Fosphenytoin
Oxcarbazepine
Phenobarbital
Phenytoin
Primidone
Vigabatrin (CYP2C9)
Phenytoin drug interactions
Increase phenytoin:
Anticoagulatns
Chloramphenicol
Cimetidine
Diltiazem
Disulfiram
Isoniazid
Phenybutazone
Sulfa-TMP
Decreased phenytoin:
Antineoplastics
Diazoxide
Folic acid
Rifampin
Carbamazepine drug interactions
Decrease carbamazepine:
Theophylline
Increase carbamazepine:
Cimetidine
Diltiazem, verapamil
Erythromycin
Isoniazid
Nefazodone
Valproic Acid drug interactions
Increase VPA:
Salicylates
Decreased VPA:
Estrogen OCPs
Meropenem
Rifampin
Carbamazepine therapeutic level
4-12 mcg/ml
Phenobarbital therapeutic level
15-40 mcg/ml
Phenytoin therapeutic level
10-20 mcg/ml
Valproic acid therapeutic level
40-100 (150) mcg/ml
Zonisamide cross reactivity
Avoid in patients with sulfa allergy
Lamotrigine starting dose
Typical: 25mg daily
with VPA: 25mg every other day
with inducers (carbamazepine, phenytoin, phenobarbital, primidone): 50mg daily
Status epilepticus Principles
- Ascertain ABCs
- Obtain lab (BG, BMB, BMP, Ca, Mg, serum conc)
- BG < 60: admin thiamine 100mg IV followed by D50%
- Administer emergency medication to stop seizure
- Administer urgent medication to prevent seizure
Administer drugs parenterally. Do not administer NMBAs.
Emergency Meds for Status Epilepticus
Lorazepam (DOC) 0.1mg/kg (max 4mg) at rate of 2mg/min
Diazepam 0.15mg/kg (max 10mg) at rate of 5mg/min
Midazolam (IM) 0.2mg/kg (max 10mg)
Urgent Meds for Status Epilepticus
FDA approved:
Phenytoin 20mg/kg
Fosphenytoin
Phenobarbital 20mg/kg
Non-FDA approved:
Valproic Acid 20-40mg/kg
Levetiracetam 40-60mg/kg
Lacosamide 200-400mg bolus
Refractory status epilepticus meds
If BZD resistant: fosphenytoin, levetiracetam, or valproate
Pentobarbital (ventilator)
Midazolam drip
Propofol (ventilator)
Epilepsy in Pregnancy
Avoid valproate acid as much as possible in nonpregnant and pregnant women
Avoid phenytoin, carbamazepine, and phenobarbital
Consider monitoring serum concentrations during pregnancy
Antiepileptics that decrease effect of OCP, patch, ring, progesterone implant
Carbamazepine
Lamotrigine
Oxcarbazepine
Phenobarbital
Phenytoin
Primirdone
Topiramate (>200mg)
Others: brivaracetam, cenobamate, clobazam, eslicarbazepine, felbamate, perampanel, rufinamide
Recommend Medroxyprogesterone injection or levonorgesterol IUD
Suicide risk in antiepileptics
All anti-epileptic meds have this warning (most siG: levetiracetam, phenobarb, primidone, topiramate, vigabatrin, tiagabine, perampanel)
Increased risk between week 1 thru week 24 of therapy
Wearing-off phenomenon
Assoc w/ Carbidopa/Levodopa
Return of Parkinson’s symptoms before next dose
Add on therapies: DA agonist, MAO-B inhibitor, COMT inhibitor (entacapone, opicapone), increasing frequency/dose of levodopa
On-off phenomenon
Assoc with Carbidopa/Levodopa
Unpredictable return of Parkinson disease symptoms without respect to dosing interval
Add on therapies: entacapone, MAO-B inhibitors (rasagiline, selegiline), DA agonist (pramipexole, ropinirole, apomorphine)
Dyskinesia in PD
Assoc w/ Carbidopa/Levodopa
Drug-induced involuntary movements
Treatment: decrease levodopa dose, add amantadine
MAO-B inhibitors
Increase dopamine in brain
Selegiline
Rasagiline
Safinamide
Caution serotonin syndrome (meperidine, other serotonergic meds)
Available as tabs and ODTs. Metabolized to amphetamine. Rasagiline interacts with Ciprofloxacin.
Carbidopa/levodopa
Carbidopa prevents peripheral conversion of levodopa to dopamine, thus increasing amount of levodopa to cross BBB and increase dopamine
Long-term ADRs = wearing-off phenomenon, on-off phenomenon, dyskinesias
Slow release as delay to effect so may need to combine with IR form
Greatest benefit for rigidity and bradykinesia > tremor, postural instability
Dopamine agonists
Apomorphine
Bromocriptine
Pramipexole
Ropinirole
Rotigotine
Titrate to effect
Dopamine related ADRs - impulsive behavior, N/V, postural hypotension
Apomorphine
DA agonist that treats off-episodes by SC inj
CI: 5HT3 antagonists (ondansetron, etc), sulfite allergy
Trimethobenzamide helps nausea
Complex dose initiation, must be done in setting w/ BP monitoring
Anticholinergics for PD
Trihexyphenidyl, benztropine
Useful only for tremor
Amantadine for PD
Reduces dyskinesias
COMT inhibitors
Prevent breakdown of dopamine to increase amount of levodopa crossing BBB
Must be used with carbidopa/levodopa
Tolcapone (severe restriction)
Entacapone
Opicapone
Diarrhea may occur after 2 weeks of initiation
Orange urine
Pimavanserin
approved for PD psychotic disorder
Antipsychotic preference in PD
Quetiapine or clozapine
Avoid typical antipsychotics, risperidone, olanzapine as they worsen motor features
Migraine highlights
Unilateral, pulsating, mod-severe intensity, aggravation by walking
Nausea, vomiting, photophobia, phonophobia
+/- aura
Tension headache highlights
Pressing or tightening (nonpulsating), mild-moderate, bilateral, no aggravation with walking
Cluster headache highlights
Several episodes of unilateral, orbital, supraorbital or temporal pain
Conjuctival injection, lacrimation, nasal congestion, rhinorrhea, facial sweating, miosis, ptosis, eyelid edema
Calcitonin gene-related peptide antagonists
Refractory prophylaxis:
SC:
Erenumab-aooe (aimovig)
Fremanezumab-vfrm (ajovy)
Galcanezumab-gnlm (emgality)
IV:
Eptinezumab (vyepti)
PO:
Atogepant (qulipta)
Rimegepant (Nurtec ODT)
Acute:
Ubrogepant
Rimegepant
Zavegepant (intranasal)
Alternate routes for triptans
SC:
sumatriptan
Intranasal:
sumatriptan
zolmitriptan
ODT:
zolmitriptan
rizatriptan
Triptan & Ergot CI
CAD
stroke
uncontrolled HTN
peripheral vascular disease
ischemic bowel disease
pregnancy
Triptan DI
MAO-I (do not use within two weeks)
Propranolol & rizatriptan (propranolol 5mg max per dose)
Antiemetics for migraine
Prochlorperazine
Metoclopramide
Chlorpromazine
Tension HA Prophylaxis
TCAs
Botox
Tension HA Acute Tx
APAP
NSAIDs (aspirin, ibuprofen, naproxen, ketoprofen, ketorolac)
w or w/o caffeine
Cluster HA Prophylaxis
Verapamil
Melatonin
Suboccipital inj of betamethasone
Lithium <0.3
Warfarin
Galcanezumab-gnlm
Steroids (prednisone 40-60mg/day taper over 3 weeks)
Cluster HA Acute
Oxygen 6-12 L/min
SC triptan > intranasal in efficacy
MS drug for pregnancy
Dimethyl fumarate (Tecfidera)
Natalizumab (Tysarbi) - possibly
Avoid all others in pregnancy
MS therapies for spasticity
- baclofen, tizanidine
- dantrolene, diazepam
- intrathecal baclofen, gabapentin
- botox
Dalfampirdine (Ampyra)
Treatment for walking impairment in MS – improves walking speed
10mg BID
Dextromethorphan/quinidine
Treatment for pseudobulbar affect (espidoes of inappropriate laughing/crying)
Quinidine blocks first pass metabolism of DM, increasing DM concentrations